Journal
NUTRIENTS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/nu11081852
Keywords
Selenoprotein-P; selenium; cardiovascular disease; prevention; supplementation
Categories
Funding
- Knut and Alice Wallenberg Foundation
- Goran Gustafsson Foundation
- Swedish Heart- and Lung Foundation
- Swedish Research Council
- Novo Nordisk Foundation
- Region Skane
- Skane University Hospital
- Swedish Foundation for Strategic Research [IRC15-0067]
- Charite Medical School Berlin
- Deutsche Forschungsgemeinschaft (DFG Research Unit 2558 TraceAge) [Scho 849/6-1]
- European Research Council [649021]
- European Foundation for the Study of Diabetes [EFSD 2015-338]
- Swedish Heart and Lung Foundation
Ask authors/readers for more resources
Selenoprotein-P (SELENOP) is the main carrier of selenium to target organs and reduces tissue oxidative stress both directly and by delivering selenium to protective selenoproteins. We tested if the plasma concentration of SELENOP predicts cardiovascular morbidity and mortality in the primary preventive setting. SELENOP was measured from the baseline exam in 2002-2006 of the Malmo Preventive Project, a population-based prospective cohort study, using a validated ELISA. Quintiles of SELENOP concentration were related to the risk of all-cause mortality, cardiovascular mortality, and a first cardiovascular event in 4366 subjects during a median (interquartile range) follow-up time of 9.3 (8.3-11) years using Cox proportional Hazards Model adjusting for cardiovascular risk factors. Compared to subjects in the lowest quintile of SELENOP, the risk of all three endpoints was significantly lower in quintiles 2-5. The risk (multivariate adjusted hazard ratio, 95% CI) decreased gradually with the lowest risk in quintile 4 for all-cause mortality (0.57, 0.48-0.69) (p < 0.001), cardiovascular mortality (0.52, 0.37-0.72) (p < 0.001), and first cardiovascular event (0.56, 0.44-0.71) (p < 0.001). The lower risk of a first cardiovascular event in quintiles 2-5 as compared to quintile 1 was significant for both coronary artery disease and stroke. We conclude that the 20% with lowest SELENOP concentrations in a North European population without history of cardiovascular disease have markedly increased risk of cardiovascular morbidity and mortality, and preventive selenium supplementation studies stratified for these subjects are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available